Novo Nordisk's semaglutide beats its counterpart liraglutide to become the next generation of weight loss innovation, and then Eli Lilly's GLP-1R/GIPR dual-target agonist tirzepatide achieves a 22.5% weight loss, surpassing semaglutide's weight loss history
Obesity has been implicated as promoting cardiovascular disease, diabetes, hypertension, and other complications, suggesting that sustained, effective weight loss may have independent cardiovascular benefit [13] [14]
If you are only eating small amounts every seven days, it is vital that those calories are nutrient-dense
Across all hematologic cancers, GLP-1RA use was associated with a 54% lower risk compared to insulin
The nature of the suppression is worth describing because it differs from what most people expect
But collagen powders, drinks, and gummies can be pricey, which is why many creators are turning to plain gelatin